Niagen Bioscience Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Niagen Bioscience Inc (NAGE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Niagen Bioscience Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 129M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-7.7% annualized vs trailing 12 months).
- Scale: Niagen Bioscience Inc ranks #8 of 37 companies by market capitalization in the Legal Cannabis industry, holding 2.2% of industry market cap.
- Peer revenue share: Niagen Bioscience Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NAGE Sales vs. its Competitors, Q2 2026
Niagen Bioscience Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Legal Cannabis industry grew revenue 34.7% year over year, combined, vs -4.3% for Niagen Bioscience Inc. Niagen Bioscience Inc's share of combined industry revenue moved from 1.30% to 0.92%, a loss of 0.38 percentage points.
Niagen Bioscience Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Niagen Bioscience Inc | Yes | Yes | Yes | No |
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 50.00 % (3 of 6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NAGE Stock Performance relative to its Competitors
NAGE Stock Performance relative to High-Confidence Competitors
NAGE Stock Performance relative to Similar-Size Competitors
NAGE Stock Performance relative to Similar Growth & Profitability Competitors
Niagen Bioscience Inc's Comment on Competition and Industry Peers
Niagen Bioscience Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| BASF | Named by the company | 85% |
| Lonza Group Ltd | Named by the company | 85% |
| US Pharmacopoeia | Named by the company | 85% |
| Glanbia plc | Named by the company | 85% |
| Royal DSM | Named by the company | 85% |
| Elysium Health | Named by the company | 85% |
| MilliporeSigma | Named by the company | 85% |
| LGC Standards Ltd. | Named by the company | 85% |
| Sabinsa Corporation | Named by the company | 85% |
| Extrasynthese | Named by the company | 85% |
| Phytolab | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Niagen Bioscience Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Niagen Bioscience Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Niagen Bioscience Inc | Tru Niagen Consumer Product 81.12 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
